Phocas Financial Corp. Has $6.01 Million Holdings in PAREXEL International Corporation (PRXL)
Phocas Financial Corp. boosted its stake in PAREXEL International Corporation (NASDAQ:PRXL) by 4.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,200 shares of the medical research company’s stock after acquiring an additional 3,088 shares during the quarter. Phocas Financial Corp. owned about 0.14% of PAREXEL International Corporation worth $6,014,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio boosted its holdings in PAREXEL International Corporation by 4.5% in the 1st quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock worth $108,000 after acquiring an additional 73 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in PAREXEL International Corporation by 10.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,986 shares of the medical research company’s stock worth $173,000 after acquiring an additional 180 shares during the period. Advisor Group Inc. boosted its holdings in PAREXEL International Corporation by 75.1% in the 2nd quarter. Advisor Group Inc. now owns 2,000 shares of the medical research company’s stock worth $173,000 after acquiring an additional 858 shares during the period. Mogy Joel R Investment Counsel Inc. purchased a new position in PAREXEL International Corporation in the 2nd quarter worth approximately $204,000. Finally, Invictus RG purchased a new position in PAREXEL International Corporation in the 1st quarter worth approximately $158,000. Hedge funds and other institutional investors own 87.45% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/16/phocas-financial-corp-has-6-01-million-holdings-in-parexel-international-corporation-prxl.html.
Shares of PAREXEL International Corporation (NASDAQ PRXL) traded down 0.02% during trading on Monday, hitting $88.08. The company’s stock had a trading volume of 7,021,106 shares. The firm’s 50 day moving average is $87.85 and its 200-day moving average is $79.27. PAREXEL International Corporation has a 1-year low of $51.16 and a 1-year high of $88.10. The company has a market capitalization of $4.50 billion, a P/E ratio of 42.76 and a beta of 0.77.
PAREXEL International Corporation (NASDAQ:PRXL) last released its earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.08. The firm had revenue of $557.20 million for the quarter, compared to analyst estimates of $537.59 million. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. During the same quarter last year, the firm posted $0.94 EPS. Analysts forecast that PAREXEL International Corporation will post $4.06 EPS for the current fiscal year.
PRXL has been the subject of a number of analyst reports. Zacks Investment Research upgraded PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price target for the company in a report on Thursday, August 31st. BidaskClub cut PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Barclays PLC cut PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target for the company. in a report on Tuesday, June 20th. Jefferies Group LLC restated a “hold” rating and issued a $88.10 price target on shares of PAREXEL International Corporation in a report on Wednesday, June 21st. Finally, Raymond James Financial, Inc. upgraded PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a report on Tuesday, June 20th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $75.92.
PAREXEL International Corporation Company Profile
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Receive News & Stock Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related stocks with our FREE daily email newsletter.